In addition, the team discovered that plasma total tau—not just the modified pTau217 form—was elevated in newborns. This is ...

Alzheimer’s disease is characterized by certain key changes in the brain. Among them are the development of two kinds of ...

AMT-130 has been granted Breakthrough Therapy designation and Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA.

The gene therapy company uniQure has announced top-level data from its trial of AMT-130, a new gene therapy designed to treat Huntington’s disease.

Pivotal study met primary endpoint; high-dose AMT-130 demonstrated statistically significant 75% disease slowing at 36 months as measured by ...

Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, today announced the ...

Post-CAR T infection prophylaxis should follow European Hematology Association/European Society for Blood and Marrow ...

Qure N.V. (NASDAQ:QURE) on Wednesday released topline data from the pivotal Phase 1/2 study of AMT-130 for Huntington’s disease. Huntington’s disease is an inherited condition in which nerve cells in ...

Kerala has witnessed a notable increase in cases of a brain-eating amoeba in 2025, with a higher survival rate compared to the global average. Experts highlight the importance of rapid diagnosis, and ...

Researchers in Japan discovered that Parkinson’s patients diagnosed in their 80s are far more likely to show signs of amyloid ...

Huntington’s disease has been successfully treated for the first time using a gene therapy, which may be available in the US ...